|
| Press Releases |
|
 |
|
| Friday, March 13, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| On 12 March 2026, China Medical System Holdings Limited is pleased to announce that its subsidiary, Dermavon Holdings Limited has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix(R)) (the "Product", marketed as Opzelura(R) in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. more info >> |
|
| Thursday, March 5, 2026 |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| more info >> |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008") received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration ("NMPA") on 4 March 2026. more info >> |
|
| Tuesday, February 24, 2026 |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| more info >> |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China more info >> |
|
| Friday, January 30, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
| Wednesday, July 16, 2025 |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| more info >> |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
ASEAN Enterprises Move from AI Experiments to Engineering-Driven Deployment
Apr 16, 2026 01:52: JST
|
|
|
Exito Media Concepts Announces the 46th Edition of the Digital Transformation Summit Malaysia 2026
Apr 16, 2026 01:41: JST
|
|
|
GMG Doubles Energy Density of 6 Minute Charging Graphene Aluminium-Ion Battery
Apr 15, 2026 19:59 HKT/SGT
|
|
|
Hitachi Energy and Samsung C&T expand strategic collaboration to accelerate grid infrastructure and reinforce energy security
Apr 15, 2026 18:17 JST
|
|
|
Mitsubishi Motors' Outlander PHEV Ranks No. 1 in Japan's PHEV Sales Category for the Second Consecutive Year
Apr 15, 2026 18:01 JST
|
|
|
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies
Apr 15, 2026 17:00 HKT/SGT
|
|
|
品創控股深化AI產業佈局 賽博幻境回聲生態戰略全球啟動
Apr 15, 2026 15:14 HKT/SGT
|
|
|
品创控股深化AI产业布局 赛博幻境回声生态战略全球启动
Apr 15, 2026 15:14 HKT/SGT
|
|
|
營收1648.9億創新高 MSCI ESG評級AAA 賽力斯彰顯豪華新能源車企硬核實力
Apr 15, 2026 15:07 HKT/SGT
|
|
|
营收1648.9亿创新高 MSCI ESG评级AAA 赛力斯彰显豪华新能源车企硬核实力
Apr 15, 2026 15:07 HKT/SGT
|
|
|
自主研发AI鉴定技术领跑二手市场 中国二手新消费平台「转转」进军香港
Apr 15, 2026 13:28 HKT/SGT
|
|
|
ASEAN Enterprises Move from AI Experiments to Engineering-Driven Deployment
Apr 15, 2026 13:06 HKT/SGT
|
|
|
自主研發AI鑒定技術領跑二手市場 中國二手新消費平台「轉轉」進軍香港
Apr 15, 2026 12:36 HKT/SGT
|
|
|
Exito Media Concepts Announces the 46th Edition of the Digital Transformation Summit Malaysia 2026
Apr 15, 2026 11:05 HKT/SGT
|
|
|
いすゞとトヨタ、国内初の量産FC小型トラックの共同開発を決定
Apr 15, 2026 11:05: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
